Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
ESMO Open|September 9, 2022
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancerR Wuerstlein, P Ellis, F Montemurro, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 18, 2023
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trialN Harbeck, P A Fasching, R Wuerstlein, et al.
Current Medical Research and Opinion|March 15, 2016
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancerR Wuerstlein, K Sotlar, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxelU A Nitz, O Gluz, M Christgen, et al.
ESMO Open|April 19, 2023
Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registryK Riecke, V Müller, T Neunhöffer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PETA Gennari, E Brain, A De Censi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trialO Gluz, S Kuemmel, U Nitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 6, 2025
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trialsM Graeser, O Gluz, C Zu Eulenburg, et al.
ESMO Open|August 15, 2025
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)M Hamann, M Christgen, O Gluz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 18, 2026
Clinical and molecular biomarkers for prediction of endocrine response after short preoperative endocrine therapy in the WSG ADAPT-HR+/HER2- and ADAPTcycle trials (N=7914)O Gluz, U Nitz, M Christgen, et al.
Pageof 3